← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Genphar, Inc.
Mount Pleasant, SC
$5,150,722
Total funding
4
Grants
Funding over time
peak $1.3M · FY2006–09$2M$1.5M$1M$500K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$5,150,722 · 4
By mechanism
U01$4,238,466 · 1
R43$912,256 · 3
Investigators at Genphar, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical evaluation of a trivalent Marburg vaccine$1,092,086
U01 · FY2007 · AI
Preclinical evaluation of a trivalent Marburg vaccine$1,087,854
U01 · FY2008 · AI
Preclinical evaluation of a trivalent Marburg vaccine$1,083,681
U01 · FY2009 · AI
Preclinical evaluation of a trivalent Marburg vaccine$974,845
U01 · FY2006 · AI
New Phenotypic HIV-1 Drug Resistance Assay Validation$255,290
R43 · FY2002 · AI
Development of a safe and effective chikungunya virus vaccine$218,621
R43 · FY2008 · AI
Development of a safe and effective chikungunya virus vaccine$215,117
R43 · FY2009 · AI
New Phenotypic HIV-1 Drug Resistance Assay Validation$124,858
R43 · FY2003 · AI
A NOVEL ADENOVIRUS-BASED TETRAVALENT DENGUE VACCINE$98,370
R43 · FY2002 · AI